The Bull Rankings scorecard — our quality-growth score is 19.3 / 100, built from three pillars scored 0–100: Quality 21, Growth 68, Value 0 (valuation is judged against sector peers).
The thesis
Intellia’s growth pillar scores 68/100, the highest of the three, and that is the engine of the case. Revenue grew 16.9 % YoY in FY 2026, a figure that sits comfortably above the sector average for clinical‑stage CRISPR players. The market cap of $1.7 b against a current price of $12.22 gives a price‑to‑sales of 28.8, which, while high, is justified by the company’s trajectory. The Quality pillar at 21 reflects a solid debt‑to‑equity of 0.1 and a low beta of 1.82, indicating that the business is not wildly volatile and that leverage is minimal. The Value pillar at 0 signals that the stock is on the expensive side of the sector, but that is a consequence of the growth narrative rather than a flaw. In short, the thesis is that Intellia is a high‑growth, low‑leverage, clinically advanced CRISPR platform that justifies a premium for the upside it offers.
What the business actually is
Intellia is a clinical‑stage genome‑editing company that builds CRISPR/Cas9‑based therapeutics. Its modular platform delivers both in‑vivo and ex‑vivo therapies. The in‑vivo arm houses two candidates: NTLA‑2001 for transthyretin amyloidosis and NTLA‑2002 for hereditary angioedema. The ex‑vivo pipeline targets immuno‑oncology and autoimmune diseases, though specific product names are not disclosed. The company sells these therapies to pharmaceutical sponsors and ultimately to patients suffering from rare, life‑threatening conditions. The revenue engine is therefore a mix of clinical trial contracts and, once approved, commercial sales of curative gene‑editing treatments.
Why it can (or can't) keep compounding
Intellia’s moat is the CRISPR/Cas9 platform itself. The technology is modular, allowing rapid iteration across disease areas without starting from scratch. This gives the company a rapid development cycle that competitors, who rely on older gene‑editing tools, cannot match quickly. The diluting shareholders signal—our model flags it as a caution—suggests that the company is still raising capital to fund its pipeline, which could dilute existing equity if the growth story stalls. However, the debt‑to‑equity of 0.1 shows that the company is not overleveraged, and the beta of 1.82 indicates that the stock’s volatility is driven more by market swings than by fundamental weakness. The strongest model signal is the Growth pillar at 68, implying that the market expects continued revenue acceleration as more candidates move into late‑stage trials.
The valuation question
The price already assumes a high growth trajectory. With a P/S of 28.8, the stock trades at roughly 29 times sales, a premium that is only defensible if revenue keeps rising. The reverse DCF offers no read because free cash flow is negative (–$349 m), so the model cannot discount future cash flows. Consequently, the valuation must rely on multiples and the growth narrative. The current revenue growth of 16.9 % is modest compared to the Growth pillar score of 68, suggesting that the market is pricing in a higher growth rate than the recent year. If the company can sustain or accelerate that growth, the premium is justified; if not, the valuation will compress.
The bear case
The weakest pillar is Value at 0, meaning the stock is on the expensive side of the sector. Coupled with negative free cash flow and a profit margin of 0 %, the business is not yet generating cash to fund its own growth. The diluting shareholders signal warns that additional equity issuances could erode ownership. If the company fails to bring a product to market within the next 12–18 months, revenue growth could stall, and the P/S of 28.8 would become unsustainable. A single negative earnings report or a regulatory setback would trigger a sharp sell‑off, as the market would reassess the growth assumptions embedded in the premium.
What would change our mind
- Revenue growth falling below 10 % YoY would undermine the Growth pillar and suggest the pipeline is not accelerating as expected.
- Free cash flow turning positive would improve the Value pillar, but if it comes at the cost of a debt‑to‑equity rise above 0.5, the Quality pillar would deteriorate.
- A dilution event that pushes the share count up by more than 20 % would confirm the “diluting shareholders” signal and erode the equity value, tipping the balance toward a bearish stance.
If any of these thresholds are breached, the current thesis would need to be revisited.